How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes by Arnolds, S et al.
How pharmacokinetic and pharmacodynamic principles
pave the way for optimal basal insulin therapy in type 2
diabetes
S. Arnolds, B. Kuglin, C. Kapitza, T. Heise
Introduction
Endogenous insulin secretion, which is tightly regu-
lated in healthy people to maintain euglycaemic
plasma glucose levels between 4 and 6 mmol⁄l, con-
sists of a rather constant, although still pulsatile,
basal insulin secretion pattern complemented by
markedly increased prandial insulin secretion. The
latter depends on individual need and is highly
variable in terms of quantity and duration (1). The
main role of basal insulin is to limit lipolysis and
hepatic glucose production in the fasting state, espe-
cially during the night, while ensuring sufﬁcient glu-
cose for cerebral function. The primary task of
prandial insulin is to suppress hepatic glucose
production and stimulate utilisation of glucose
by muscle, thus preventing hyperglycaemia after
meals (2).
Numerous efforts have been undertaken by phar-
maceutical companies to develop insulin formula-
tions that closely mimic the kinetics of this complex
endogenous insulin secretion pattern. Consequently,
a variety of insulin analogues are now available for
clinical use, including rapid-acting insulin analogues
that can be administered before or during meals for
prandial control (regular human insulin, insulin
lispro, insulin aspart and insulin glulisine), long-
acting insulin analogues that can be administered
once- or twice-daily for basal insulin supply (NPH
insulin, insulin glargine and insulin detemir) and
insulin premixes that contain both basal and prandial
insulins in a single injection (3). None of the ana-
logue premixes contains NPH.
This pedagogical review describes several key prin-
ciples of pharmacokinetics (PK) and pharmacody-
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Message for the Clinic
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doi: 10.1111/j.1742-1241.2010.02470.x 1415namics (PD) used in diabetes research. It further
describes how these principles can be translated into
clinical diabetology. The content has a particular
focus on basal insulins for type 2 diabetes, but the
concepts are generally applicable for many therapeu-
tics. Our goal has been to address common questions
on insulin pharmacology that arise frequently in dis-
cussions with general practitioners.
Question 1: What is the pharmacology
of endogenous insulin?
Insulin is secreted from pancreatic b-cells located in
the islets of Langerhans and enters the circulation
primarily in response to a rise in blood glucose.
Apart from stimulating peripheral glucose utilisation
in the main insulin-dependent tissues, i.e., skeletal
muscles and adipose tissue, insulin antagonises the
effect of glucagon in the liver by inhibiting glucose
and ketone body production. In addition, because of
the anatomy of the blood circulation within the
Langerhans islets, insulin directly inhibits glucagon
secretion from neighbouring pancreatic a-cells inde-
pendently of blood glucose. In healthy non-obese
adults, insulin is secreted at a basal rate of 0.5–1 U⁄h
(4), resulting in plasma concentrations of 5–
15 lU⁄ml in fasting conditions (5). Within 30–
60 min of a meal, insulin levels rapidly increase to
peak concentrations of 60–80 lU⁄ml and return to
baseline 2–4 h later (5). In general, obese subjects
show much higher basal and postprandial levels.
Once released from b-cells or a subcutaneous
depot, insulin clearance appears to be a rather com-
plex process. The liver and kidney are the main sites
of insulin degradation, but insulin clearance is prob-
ably also mediated by insulin receptor dynamics and
depends highly on insulin concentration (6).
Question 2: What are the limitations
of PK parameters relative to PD
parameters for understanding
therapeutic insulins?
In general, PK may be regarded as what the body
does to a drug, and PD as what a drug does to the
body. PK comprises the relationship between drug
input – which includes adjustable factors such as
dose, dosage form, frequency and route of adminis-
tration – and the concentration achieved with time.
PD, in contrast, comprises the relationship between
drug concentration and both the intended and
adverse effects produced with time (7). A simpliﬁed
PK⁄PD scheme is shown in Figure 1.
The PD of a drug, i.e., the duration of its biologi-
cal effects after administration, are the product of
numerous target interactions and⁄or downstream
signalling events that occur in multiple cells and
organs in response to the drug. The kinetics of these
events occurs over an extended time frame relative
to that of drug availability. In the speciﬁc case of
insulins, the temporal separation between the PK
and PD proﬁles (Figure 2) is the result of a series of
insulin-speciﬁc phenomena, including the fraction
and rate of absorption from subcutaneous tissue, the
rate of binding to insulin receptors and subsequent
induction of metabolic processes, including elimina-
tion. Pharmacological proﬁles of different insulin
preparations can only be understood when these PD
effects are taken into account. This is especially true
when considering the long-acting basal insulins (8).
One PK term in particular, ‘half-life’, often pre-
sents signiﬁcant misunderstandings when considered
in relation to insulins. The elimination half-life (t1 ⁄ 2)
is deﬁned as the time necessary for the plasma con-
centration, as well as the amount of the drug in the
body, to fall by one half after the distribution phase
has ended and the elimination phase has begun (Fig-
ure 2). Thus, it always takes at least four elimination
half-lives from the time of peak plasma concentra-
tion for a drug to be nearly completely eliminated
from the body (50% + 25% + 12.5% + 6.25% =
93.75%). It is important to know the elimination
half-life of a drug when designing or prescribing a
drug to evaluate its potential for accumulation.
After secretion from the pancreas, the estimated
biological half-life of insulin in the blood stream lies
between 3 and 10 min. This value, however, is irrele-
vant for insulin injections in diabetic patients
because, as the circulating hormone is cleared from
the blood, fresh insulin is continuously released from
the subcutaneous depot produced by the injection.
For commercial preparations, insulin levels in blood
are driven primarily by the more prolonged absorp-
tion rate from the depot, which lasts several hours
for all insulin formulations available. As a result, the
elimination half-life is a more clinically relevant
parameter than the biological half-life.
These considerations also resolve what some clini-
cians may mistakenly view as a paradox regarding
long-acting insulins, i.e., that they have elimination
half-lives (often denoted in this context as ‘terminal
half-lives’) of only 5–7 h, and yet are recommended
to be dosed once-daily. The key consideration here is
Dose 
Concentration/ 
exposure to 
drug within 
body 
Desired 
and 
adverse 
effects 
PK  PD 
Figure 1 Relationship between pharmacokinetics (PK) and
pharmacodynamics (PD)
1416 Optimal basal insulin therapy in type 2 diabetes
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, September 2010, 64, 10, 1415–1424that the elimination half-life only applies after the
drug has been fully distributed. As a result of the
slow absorption of these agents, the distribution
phase can last for many hours. In the case of insulin
detemir, for instance, the distribution phase in adults
lasts approximately 8 h (9). The remaining 16 h in
the 24-h period is covered by 2–3 elimination half-
lives. Given the temporal delay for PD effects (Fig-
ure 2), insulin levels remain high enough across a
24-h period to support once-daily administration.
Finally, another technical issue concerning insulin
PK is the lack of methodologies for comparing
absolute values of serum concentrations of different
insulins, including basal insulin preparations. Well-
established assays are available for NPH insulin and
insulin detemir (10), but for insulin glargine, neither
commercial assays nor optimal alternative methods
are available (11). Consequently, PK parameters
published for insulin glargine are based on indirect
measures and may, therefore, be less precise.
Question 3: What is the best method
to investigate insulin PD?
The following challenges have to be borne in mind
when assessing PD measurements of insulins, or
other blood glucose-lowering agents, in human sub-
jects. First, the initial⁄basal blood glucose level prior
to the administration of insulin is of importance, as
the lower the blood glucose, the higher the insulin
sensitivity and vice versa. Second, there is a high
inter- and intra-individual variability with respect to
both the effects of intake of a speciﬁc amount of car-
bohydrates and a given dose of insulin (this necessar-
ily imposes limitations on oral glucose tolerance
and standard meal tests, as well). Third, hypoglyca-
emia and consequent counter-regulation following
an insulin injection limit experiments in healthy
volunteers.
The solution to the ﬁrst challenge is to induce and
maintain a ﬁxed initial blood glucose level in study
subjects so that they have comparable metabolic situ-
ations and insulin sensitivities at the beginning of
the study. The solution to the second is to ensure
that subjects fast during the investigational period to
avoid problems related to food intake. Finally, the
solution to the third is to infuse glucose into patients
who have just received exogenous insulin to prevent
hypoglycaemia and counterregulation. This is the
approach taken in glucose-clamp experiments.
The glucose-clamp technique is the gold standard
method for investigating PD proﬁles of insulin prep-
arations (12). In clamp studies, insulin is injected
into subjects, and the subsequent PD effects are
investigated by preventing the expected decrease in
blood glucose concentration with a variable glucose
infusion that ‘clamps’ the blood glucose to a prede-
termined level. A plot of the amount of glucose
infused over time, expressed as glucose infusion rate
(GIR) in mg⁄kg⁄min necessary to maintain blood
glucose at the clamp level, accurately reﬂects the PD
effect of the study insulin (13). Figure 2 shows the
PK (serum insulin concentration) and PD (GIR)
proﬁles of a soluble insulin during a euglycaemic
glucose clamp. Note the temporal shift between the
PK and PD curves.
A number of parameters of interest can be derived
from PD proﬁles (Figure 3). These include the area
s.c. injection
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Figure 2 Comparison of pharmacokinetics (PK) (serum insulin concentrations) and pharmacodynamics (PD) (glucose
infusion rate) over time after a single subcutaneous injection of insulin. The difference between the two curves illustrates
the temporal separation between PK and PD effects
Optimal basal insulin therapy in type 2 diabetes 1417
ª 2010 Blackwell Publishing Ltd Int J Clin Pract, September 2010, 64, 10, 1415–1424under the curve (AUC), i.e., the overall glucose-low-
ering effect⁄glucose disposal, and GIRmax and tmax,
i.e., the magnitude and time of peak effect, respec-
tively. Also relevant to patients are the time to 50%
of maximum effect (early t50%), i.e., the onset of
action of the respective insulin, and the time when
the maximum effect has fallen again by 50% (late
t50%), i.e., the vanishing effect⁄end of action. For
basal insulins, important parameters include: dura-
tion of action, i.e., the time period between insulin
injection and end of action; and the end of action,
i.e., the time from injection of the study insulin to
an increase in serum glucose concentration above a
predetermined value (often 8.3 mmol⁄l) (13). The
duration of action can only be measured reliably in
people with type 1 diabetes. In such patients, a
declining metabolic effect of the study insulin causes
an immediate rise in blood glucose. By contrast, in
healthy people or patients with type 2 diabetes, dura-
tion of action can be overestimated because of
endogenous insulin secretion. Duration of action is
of relevance in patients who are deciding whether to
inject basal insulin once- or twice-daily. Figures 4
and 5 provide GIR curves on rapid-acting and long-
acting insulins.
Glucose clamps can be performed ‘manually’ or,
more accurately, by an automated procedure using a
Biostator (MTB Medizintechnik, Ulm, Germany),
which measures the arterialised blood glucose con-
centration every minute and adjusts the GIR accord-
ing to a negative feedback algorithm based on the
deviations of the glucose measurements from the
clamp glucose target level (8).
Question 4: What should the ‘ideal’
basal insulin look like and how do
current products compare?
From a pharmacological point of view, key character-
istics of an ‘ideal’ basal insulin should include:
• The PD proﬁle should be ﬂat (peakless) and
should be associated with a low risk of hypoglyca-
emia (which might be caused by nocturnal peak
activity several hours after injection).
• The duration of action should be around 24 h to
control fasting plasma glucose (FPG) with just one
injection per day.
• Variability within individual patients should be low,
meaning that identical doses of insulin administered
to the same patient on different occasions should lead
to identical and predictable effects, thus lowering the
risk of hypoglycaemia or hyperglycaemia.
The next sections describe current basal insulin
preparations in terms of these ideal characteristics.
NPH insulin
Neutral Protamine Hagedorn (NPH), introduced by
Hagedorn in 1946, contains protamine and insulin in
‘isophane’ amount, i.e., there is neither an excess of
protamine nor of insulin. The addition of zinc at
low concentrations allows the protamine to form
crystals with insulin at neutral pH. NPH insulin is a
suspension and must be properly re-suspended
before injection, which may contribute to increased
GIRmax
G
l
u
c
o
s
e
 
i
n
f
u
s
i
o
n
 
r
a
t
e
 
(
m
g
/
k
g
/
m
i
n
)
 
Time (min) 
tmax tearly 50% tlate 50 % T
AUC0-T = 2838 AUC0-∞ ∞ = 3032
s.c. injection of 16 IU regular insulin
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
–1
–2
0 60 120 180 240 300 360 420 480 540 600 660 720 780 840 900
tearly 50%  tmax  tlate 50% 
Figure 3 Key pharmacodynamics (PD) parameters from a glucose-clamp experiment
0
0
2
4
6
8
10
12
123456789 1 0
Short-acting analogue (lispro)
Regular human insulin
Inhaled insulin
Time (h)
G
l
u
c
o
s
e
 
i
n
f
u
s
i
o
n
 
r
a
t
e
 
(
m
g
/
k
g
/
m
i
n
)
Figure 4 Glucose infusion rates in glucose-clamp
experiments on rapid-acting insulins (64)
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Figure 5 Glucose infusion rates in glucose-clamp
experiments on long-acting insulins
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resentative glucose-clamp study (15) described the
PK and PD of NPH insulin and highlighted its
limitations: a short duration of action (14 ± 3 h), a
signiﬁcant peak at 4.5 ± 0.5 h and a high inter-
individual variability.
Insulin glargine
In 2000, insulin glargine became the ﬁrst basal insu-
lin analogue available. Insulin glargine differs from
human insulin at position A21 of the A chain (sub-
stitution of asparagine with glycine) and position
B31 and B32 of the B chain (addition of two argi-
nines). These changes shift the isoelectric point from
pH 5.4–6.7 (16). Insulin glargine is injected as a clear
acidic solution (pH 4), which forms microprecipi-
tates that must dissolve before absorption can take
place. Precipitation and slow re-dissolution are
inherently associated with substantial variability.
Nonetheless, the time–action proﬁle of insulin glar-
gine is ﬂatter and of longer duration compared with
NPH insulin (15).
Insulin detemir
Insulin detemir differs from human insulin; in that,
threonine at position B30 has been removed and that
lysine at B29 has been acylated with a 14-carbon fatty
acid (myristic acid). The prolonged duration of
action for insulin detemir is attributable to a combi-
nation of increased self-association (hexamer stabili-
sation and hexamer–hexamer interaction) and
albumin binding because of the acylation. Insulin det-
emir is highly albumin-bound (98.8%) in the intersti-
tial ﬂuid and in plasma (17). The analogue is
supplied as a clear neutral solution and remains in
solution in the subcutaneous depot, in the circulation
and in the target tissues until interaction with the
insulin receptor. Absorption of insulin detemir is
therefore dependent on neither appropriate re-sus-
pension before injection and dissolution of crystals,
as is the case with NPH insulin, nor on formation
and re-dissolution of microprecipitates, as is the case
for insulin glargine. Insulin detemir has a much
ﬂatter and longer time–action proﬁle compared with
NPH insulin (13), as well as reduced variability
compared with insulin glargine (13).
Question 5: What are the results from
PD glucose-clamp studies with basal
insulin analogues?
The information of most clinical relevance for basal
insulins involves the critical issues of ﬂatness,
duration of action and variability. For ﬂatness and
duration of action, one needs to look at the GIR
curves from a number of published glucose-clamp
studies (15,18–22), which have been summarised in a
recent review (13). For insulin glargine, all available
studies, with one exception (15), showed a very gen-
tle rise and fall over time, indicating a relatively ﬂat
activity proﬁle with some evidence of a very broad,
albeit small, peak. Mean duration of action was close
to 24 h in patients with type 1 diabetes and at least
24 h in people with type 2 diabetes around the
clinically relevant dose range of 0.4 U⁄kg. The same
conclusions – a much ﬂatter proﬁle than NPH insu-
lin and duration of action of around 24 h – were
consistently proven for insulin detemir by all studies,
apart from one outlier (22).
A recent glucose-clamp study (23) compared dura-
tion of action of insulin glargine and insulin detemir
after single and repetitive doses (administration over
7 days) in subjects with type 1 diabetes. Both basal
insulins had durations of action approximating 24 h,
although the duration of action after a single dose
was shorter for insulin glargine than insulin detemir
(19.8 ± 14.4 h vs. 25.9 ± 4.6 h, respectively), whereas
the durations of action after repetitive doses were
23.3 ± 4.9 h for insulin detemir and 27.1 ± 7.7 h for
insulin glargine. In addition, two other clamp studies
in type 1 (21) and type 2 diabetes (20) showed that
the duration of action of basal insulin analogues was
dose-dependent, i.e., higher doses resulted in longer
durations of action, as is observed for all insulins
and, indeed, for all pharmaceuticals.
‘Within-subject variability’ is deﬁned as the degree
of difference in the glucose-lowering effect from one
injection to another within the same patient. For
basal insulin analogues, this relates to the consistency
of the 24-h PD proﬁle from one injection to the
next, which can only be assessed in repeat clamp
studies. Such a study (19) was performed in subjects
with type 1 diabetes who underwent 24-h glucose-
clamp analyses with insulin detemir (n = 18), insulin
glargine (n = 16) or NPH insulin (n = 17). Each
subject received four single subcutaneous doses of
each basal insulin on four different clamp days; all
insulins were administered at the same dose
(0.4 U⁄kg). Insulin detemir was associated with sig-
niﬁcantly less within-subject variability than both
NPH insulin and insulin glargine. The coefﬁcients of
variation for the PD end-point GIR–AUC(0–24 h)
were 27% for insulin detemir, 48% for insulin glar-
gine and 68% for NPH insulin. Lower within-subject
variability for insulin detemir was also conﬁrmed in
patients with type 2 diabetes in another clamp study
(20), although the latter study had the limitation that
no replicate experiments with identical doses were
conducted, so the results had to be dose-corrected to
investigate variability.
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glucose-clamp studies predict clinical
outcome data?
Ideally, results from glucose-clamp studies on basal
insulin analogues should be applicable in the clinic
when one wants to determine the optimal balance
between metabolic control and hypoglycaemia. A
basal insulin analogue, when compared with NPH
insulin, should result in: comparable metabolic con-
trol with less hypoglycaemic episodes; improved met-
abolic control with comparable hypoglycaemic
events; or, in the best case scenario, improvement in
both. Does this actually hold true in phase 3 trials?
Insulin glargine vs. NPH insulin
In a number of clinical trials, patients with type 2
diabetes exhibited comparable HbA1c reductions (24–
27) and rates of achieving target HbA1c goals
(£ 7.0%) (24,27) when administered insulin glargine
or NPH insulin. Moreover, there was a consistent
and signiﬁcant reduction in hypoglycaemia risk with
insulin glargine compared with NPH insulin for both
overall symptomatic (11%, p = 0.0006) and noctur-
nal (26%, p < 0.0001) hypoglycaemic events (24,28).
In one meta analysis (24), risks of overall severe and
severe nocturnal hypoglycaemia were reduced by
46% (p = 0.0442) and 59% (p = 0.0231), respec-
tively, although another (25) did not ﬁnd signiﬁcant
differences in conﬁrmed or severe episodes. One
study (27) showed a lower rate of hypoglycaemic
excursions and less variability of FPG in subjects tak-
ing insulin glargine compared with NPH insulin.
Insulin detemir vs. NPH insulin
Large randomised clinical trials comparing insulin
detemir and NPH insulin have demonstrated that
glycaemic control with insulin detemir was similar
to, or better than, NPH insulin (29,30). Use of insu-
lin detemir was associated with a signiﬁcant reduc-
tion in the risk of nocturnal hypoglycaemia in the
majority of studies (31–37) [up to 87% or 90% risk
reduction compared with NPH insulin (35,38)].
Insulin detemir therapy also provided more pre-
dictable glycaemic control and less intra-patient vari-
ability than NPH insulin in both type 1 and type 2
diabetes (29,32,36,38–42). In most trials (32,36,38–
42), intra-patient variation in self-measured FPG was
signiﬁcantly lower with insulin detemir than NPH
insulin. In addition, nocturnal plasma glucose pro-
ﬁles were more stable, with lower glucose ﬂuctua-
tions (32,36). Increased intra-patient variability with
insulin therapy may increase the risk of hypoglyca-
emia, as was shown from a meta analysis (43) and
two further publications (44,45). These studies
showed a positive correlation between the incidence
of hypoglycaemia and the coefﬁcients of variation in
FPG: a reduction of 2.7% in the within-patient varia-
tion in FPG resulted in 2.77% fewer hypoglycaemic
events per subject per year, independent of the type
of treatment (43). Thus, a decrease in intra-patient
variability, as seen with insulin detemir, is worth
noting – not only from glucose-clamp study results,
but also from the clinical data described above.
Insulin glargine vs. insulin detemir
Four head-to-head clinical trials comparing insulin
glargine and insulin detemir have been published,
including one study in type 1 diabetes (46) and three
in type 2 diabetes (47–49). One 52-week treat-to-tar-
get trial evaluated both analogues in a basal-bolus
regimen with mealtime insulin aspart in 319 type 2
subjects treated with oral antidiabetic drugs (OADs)
or insulin, with or without OADs (47). A second 52-
week study compared insulin detemir with insulin
glargine administered as add-on therapy to OADs in
582 insulin-naı ¨ve subjects with type 2 diabetes (48).
In both trials, insulin detemir and insulin glargine
were equally effective in optimising HbA1c. The two
analogues were associated with comparable hypo-
glycaemia risks and variabilities, but insulin detemir
therapy was associated with less weight gain. Another
head-to-head study (49) was a double-blind, rando-
mised, crossover study in subjects with type 2 diabe-
tes that included continuous glucose monitoring
after careful insulin titration over several days. In this
study, once-daily dosing of insulin detemir provided
glycaemic control similar to that of insulin glargine
over a 24-h period.
Question 7: Treatment strategies with
basal insulin analogues in type 2
diabetes: what is the evidence from
clinical trials?
According to a consensus statement from the Ameri-
can Diabetes Association and the European Associa-
tion for the Study of Diabetes (50), initiation of
insulin therapy in patients with type 2 diabetes
should start with either bedtime intermediate-acting
or bedtime or morning long-acting insulin (10 units
or 0.2 U⁄kg). A recent review on insulin therapy in
type 2 diabetes (51) also concluded that once-daily
basal insulin added to oral medication is an ideal
starting point. However, all next steps, from one to
two or even more daily injections, are controversial
and should be considered carefully with the respec-
tive patient. An important issue is the early inten-
siﬁcation of insulin therapy to achieve and keep
target HbA1c values. In the 3-year 4-T study (52–54)
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betes, 68–82% of patients received an additional type
of insulin to achieve a median HbA1c level of 6.9%
and, thus, needed ‘complex’ regimens.
A recent meta analysis on optimal insulin regi-
mens in type 2 diabetes (55) found greater HbA1c
reductions in insulin-naı ¨ve patients treated with
biphasic or prandial insulin, compared with basal
insulin [0.45% (p = 0.0006) and 0.45% (p = 0.02),
respectively], but with lesser reductions of fasting
glucose [0.93 mmol⁄l (16.8 mg⁄dl; p = 0.01) and
2.20 mmol⁄l (39.7 mg⁄dl; p < 0.00001), respec-
tively]. Moreover, minor hypoglycaemic events were
inconsistently reported as either higher than or
equivalent to basal insulin, and there was greater
weight gain with prandial compared with basal insu-
lin (1.86 kg, p = 0.0006).
In the 3-year 4-T study (52,53), 708 subjects with
type 2 diabetes and inadequate glycaemic control on
metformin and sulfonylurea were randomly assigned
to receive prandial insulin aspart, basal insulin det-
emir or biphasic insulin aspart. Starting in the sec-
ond year, sulfonylureas were replaced by an
additional insulin (basal insulin added to prandial
insulin, prandial insulin three times daily added to
basal insulin and prandial insulin at lunch added to
biphasic insulin) if HbA1c levels were above 6.5%.
An important feature of this study was its long dura-
tion and the standardisation of insulin regimens.
Less than 45% of all patients reached the HbA1c
target of £ 6.5% (and even less than one-third in the
biphasic group). In addition, there were striking dif-
ferences in outcomes between the ﬁrst and third
years. Although the basal regimen was least successful
in the ﬁrst year, it was effective after 3 years, proba-
bly because of a progressive increase of the insulin
dose. The basal insulin regimen, which was equiva-
lent to the other regimens after the ﬁrst year in
Table 1 Treatment algorithms for insulin glargine and insulin detemir in type 2 diabetes
Insulin glargine (GLAR)
Author Study/number of patients Intervention Algorithm
Riddle
(Diabetes Care 2003)
24-Week treat-to-target trial
n = 756
GLAR or NPH once daily
at bedtime
Starting dose: 10 U⁄day
If mean FPG (mmol⁄l) over previous 3 days:
‡ 5.6 to < 6.7 ﬁ 0–2 U ›
‡ 6.7 to < 7.8 ﬁ 2U›
‡ 7.8 to < 10.0 ﬁ 4U›
‡ 10.0 ﬁ 6–8 U
and no PG < 4.0 mmol⁄l
Davies
(Diabetes Care 2005)
ATLANTUS
n = 4961
GLAR;
clinic- vs. patient-managed
dose titration
Clinic-managed titration: as in Riddle study
Patient-managed titration:
2I U › every 3 days, no PG < 4 mmol⁄l
Yki-Ja ¨rvinen
(Diabetologia 2006)
36-Week LANMET trial
n = 110
Bedtime GLAR vs. NPH Patient-managed titration:
2I U › every 3 days, if FPG above
4.0–5.6 mmol⁄l, stop
titration if ‡ 1 hypoglycaemic event
Insulin detemir (DET)
Author Study details Intervention Algorithm details
Meneghini
(Diabetes Obes Metab 2007)
PREDICTIVE 303 Trial
n = 5604
DET as add-on to OAD or
as replacement of prestudy insulin
Patient-managed titration:
every 3 days: mean adjusted FPG (mmol⁄l)
< 4.4 ﬁ 3U ﬂ
4.4–6.1 ﬁ no change
> 6.1 ﬁ 3U ›
vs. physician-managed titration:
according to standard of care
Blonde
(Diabetes Obes Metab 2009)
20-Week TITRATE Trial
n = 244
DET once daily, insulin-naı ¨ve
patients on OAD
Two FPG (mmol⁄l) titration targets:
(1) 3.9–5.0
(2) 4.4–6.1
Titration as in PREDICTIVE
NPH, Neutral Protamine Hagedorn; FPG, fasting plasma glucose; OAD, oral antidiabetic drugs.
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rior to both prandial and biphasic insulin after
3 years in terms of weight gain and the rate of hypo-
glycaemia. Thus, the 4-T study supports the initia-
tion of treatment with basal insulin.
This conclusion is consistent with the concept that
fasting hyperglycaemia contributes more than post-
prandial hyperglycemias to HbA1c levels. As shown
by Monnier, the relative contribution of fasting
hyperglycaemia to HbA1c levels increased gradually
as diabetes worsened, whereas that of postprandial
glucose excursions were predominant in relatively
well-controlled patients (56). Thus, it makes sense to
focus on FPG during insulin initiation. Several
studies investigated treatment algorithms for insulin
glargine (27,57–59) and insulin detemir (60,61)
(Table 1). A number of these algorithms depend on
patient-managed self-titration, which has proven to
be safe and efﬁcacious.
Question 8: Which factors – keeping
insulin PD on one’s mind – have an
impact on appropriate (basal) insulin
substitution in ‘real life’?
Patient and⁄or physician barriers to insulin initiation
or intensiﬁcation often need to be overcome before
insulin therapy can be implemented successfully
(62,63). One of the key patient barriers is fear of
hypoglycaemia, which can be managed by appropri-
ate training, introduction of blood glucose self-moni-
toring (50,62), use of basal insulin analogues (62)
and translation of PD concepts into practical clinical
dosing regimens. Decisions on insulin dose adjust-
ments should be knowledge based. Thus, the patient
should be enabled to differentiate whether a high
fasting glucose value resulted from deﬁciency in
insulin, diet violation the prior evening or from noc-
turnal hypoglycaemia and counter-regulation. Train-
ing should be provided to deal with the speciﬁc
situations of illness, fever and demobilisation and
unplanned exercise or extra meals. General practitio-
ners who face time constraints or lack familiarity
with tailored insulin treatment should obtain contin-
uing education and should have a hot line to special-
ists for rapid consultation (63).
Conclusions
Measurements of serum insulin concentrations in
patients with diabetes do not add value to clinical
practice. Moreover, the biological half-life of insulin
is unimportant to either its efﬁcacy or duration of
action. Instead, the PD proﬁle is far more informa-
tive than the PK proﬁle in terms of determining dos-
ing frequency and expectations of efﬁcacy over a
given period of time.
The optimal method for assessing PD parameters
is the glucose-clamp technique. Results of studies
using this technique have demonstrated that insulin
glargine and insulin detemir have ﬂatter, but not
completely peakless, time–action proﬁles compared
with NPH insulin. The basal insulin analogues also
have comparable durations of action of around 24 h,
with less intra-subject variability for insulin detemir.
These conclusions have been conﬁrmed in clinical
trials, which have shown that once-daily dosing of
insulin glargine and insulin detemir is possible and
that these two basal analogues provide equal meta-
bolic control relative to NPH insulin in terms of
HbA1c. Compared with NPH insulin, use of insulin
glargine and insulin detemir is associated with less
hypoglycaemic events (particularly nocturnal ones),
lower FPG and – with a slight advantage for insulin
detemir – less intra-subject variability of fasting glu-
cose. Patients can self-titrate the two basal insulin
analogues effectively and safely by means of simple
titration algorithms.
Finally, in addition to a sufﬁcient knowledge about
insulin PD, appropriate education, empowerment
and training of both the patient and the healthcare
worker are essential to overcome potential barriers to
insulin therapy, deal with speciﬁc situations and suc-
cessfully implement everyday insulin supplementa-
tion. These steps, if followed through appropriately,
should facilitate patient care and improve quality of
life for patients with type 2 diabetes.
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